红霉素C | 1675-02-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 红霉素C
• 英文名称: erythromycin C
• 英文别名: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2R,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
• CAS: 1675-02-1
• 化学式: C₃₆H₆₅NO₁₃
• 分子量: 719.911
• InChiKey: MWFRKHPRXPSWNT-QNPWSHAKSA-N

物化性质

• 熔点：
  121-125 °C
• 沸点：
  826.2±65.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：可溶； DMSO：可溶；乙醇：可溶；甲醇：可溶；水：溶解度有限

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  50
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  205
• 氢给体数：
  6
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  红霉素C 在 甲醇 、 乙酰氯 作用下， 生成 红霉糖胺
  参考文献：
  名称：

  Erythromycin. XI.¹ Structure of Erythromycin B²

  摘要：

  DOI：

  10.1021/ja01579a060
• 作为产物：
  描述：

  红霉素 在 Suwannee River natural organic matter 作用下， 以 水 为溶剂， 生成 anhydroerythromycin 、 红霉素C 、 16-羟基红霉素 、 (3S,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-5,7,9,11,13-pentamethyl-2,10-dioxo-oxacyclotetradecane-3-carbaldehyde 、 、
  参考文献：
  名称：

  Chronic toxic effects of erythromycin and its photodegradation products on microalgae Chlorella pyrenoidosa

  摘要：

  DOI：

  10.1016/j.aquatox.2024.106922

文献信息

• Macrolide antiinfective agents
  申请人：——

  公开号：US20020055472A1

  公开（公告）日：2002-05-09

  The invention is directed towards antibacterial compounds. The invention concerns macrolide antibiotics useful as antiinfective agents.

  这项发明是针对抗菌化合物的。该发明涉及可用作抗感染剂的大环内酯抗生素。
• [EN] A NOVEL PROCESS OF LIBERATION OF ERYTHROMYCIN AND PREPARATION OF ITS SALTS<br/>[FR] NOUVEAU PROCÉDÉ DE LIBÉRATION D'ÉRYTHROMYCINE ET PRÉPARATION DE SES SELS
  申请人：CALYX CHEMICALS AND PHARMACEUTICALS LTD

  公开号：WO2014140699A1

  公开（公告）日：2014-09-18

  The present invention relates to a novel process for the liberation of Erythromycin from Erythromycin salts such as Erythromycin thiocyanate using water as a solvent in presence of a base. Erythromycin obtained by process of the present invention has purity of more than 95%. The present invention further relates to a novel process for the preparation of Erythromycin Stearate by reacting Erythromycin or its salts with stearic acid in presence of water.

  本发明涉及一种新的工艺，用水作为溶剂，在碱的存在下从红霉素硫氰酸盐等红霉素盐中解放红霉素。通过本发明的工艺获得的红霉素纯度超过95%。本发明还涉及一种新的工艺，通过在水的存在下将红霉素或其盐与硬脂酸反应，制备红霉素硬脂酸酯。
• 9-Desoxoerythromycin compounds as prokinetic agents
  申请人：Liu Yaoquan

  公开号：US20050256064A1

  公开（公告）日：2005-11-17

  9-Desoxoerythromycin compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful as prokinetic agents for treating disorders of gastric motility.

  式I中的9-去氧红霉素化合物，其中R1、R2、R3、R4和R5如本文所定义，可用作治疗胃动力障碍的促动力剂。
• Motilide compounds
  申请人：——

  公开号：US20020094962A1

  公开（公告）日：2002-07-18

  The present invention provides novel macrolide compounds of the formulas 1 wherein: R is hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 0 is hydroxyl or methoxy; R 1 is selected from the group consisting of hydrogen, hydroxyl, halide, NH 2 , OR 9 , 2 where R 9 is substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl, and R 10 and R 11 are each independently hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 1 and R 3 are each independently selected from the group consisting of hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl, or R 2 and R 3 together form a cycloalkyl or an aryl moiety; R 4 is hydrogen or methyl; R 5 is hydroxyl or oxo; R is hydrogen, hydroxyl, or OR 12 where R 12 is substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, or unsubstituted C 2 -C 10 alkynyl; R 7 is methyl, unsubstituted C 3 -C 10 alkyl, substituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 8 is unsubstituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 13 is hydrogen, unsubstituted C 1 -C 10 alkyl, substituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, or unsubstituted alkynylaryl; R 17 is hydrogen or methyl; x is a single or a double bond; and, Y is hydrogen, substituted C 1 -C 10 alkyl, unsubstituted C 1 -C 10 alkyl, substituted C 2 -C 10 alkenyl, unsubstituted C 2 -C 10 alkenyl, substituted C 2 -C 10 alkynyl, unsubstituted C 2 -C 10 alkynyl, substituted aryl, unsubstituted aryl, substituted alkylaryl, unsubstituted alkylaryl, substituted alkenylaryl, unsubstituted alkenylaryl, substituted alkynylaryl, unsubstituted alkynylaryl, unsubstituted cladinose, or substituted cladinose.

  本发明提供了具有以下结构的新型大环内酯化合物：其中：R为氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R0为羟基或甲氧基；R1选自氢、羟基、卤素、NH2、OR9、其中R9为取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基，以及R10和R11分别独立为氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R1和R3各自独立选自氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基，或R2和R3共同形成环烷基或芳基基团；R4为氢或甲基；R5为羟基或酮基；R为氢、羟基或OR12，其中R12为取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基或未取代的C2-C10炔基；R7为甲基、未取代的C3-C10烷基、取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R8为未取代的C1-C10烷基、取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R13为氢、未取代的C1-C10烷基、取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基或未取代的炔基芳基；R17为氢或甲基；x为单键或双键；Y为氢、取代的C1-C10烷基、未取代的C1-C10烷基、取代的C2-C10烯基、未取代的C2-C10烯基、取代的C2-C10炔基、未取代的C2-C10炔基、取代的芳基、未取代的芳基、取代的烷基芳基、未取代的烷基芳基、取代的烯基芳基、未取代的烯基芳基、取代的炔基芳基、未取代的炔基芳基、未取代的克拉迪诺糖苷或取代的克拉迪诺糖苷。
• Ketolide anti-infective compounds
  申请人：Li Yong

  公开号：US20050272672A1

  公开（公告）日：2005-12-08

  Compounds according to formula I wherein m is 0 or 1; X is and R 1 , R 2 , R 3 R 4 , and R 5 are as defined herein, are useful as anti-infective agents.

  根据公式I，化合物中m为0或1；X为，R1、R2、R3、R4和R5如下所定义，可用作抗感染剂。